Talk One- Escalation and De-Escalation Strategies in Early-Stage HER2-Positive Breast Cancer
Presenter: Ciara O'Sullivan, MB, BCh

Talk Two- Clinical Trials for Breast Cancer Survivors
Presenter: Kathryn J. Ruddy, MD

LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to: 

1. Describe potential factors/strategies which can guide treatment escalation and de-escalation in HER2-positive early breast cancer
2. Summarize the scientific rationale of the CompassHER2 Trials
3. Describe other ongoing escalation and de-escalation trials for HER2+ early breast cancer

4. Describe the recently-opened SyMPTOM trial, which focuses on endocrine therapy adherence
5. Review the soon-to-open i-mammo trial, which focuses on surveillance mammography in older survivors
6. Describe other ongoing and near-future symptom control trials for breast cancer survivors  

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

To claim credit for livestream participation in this course, learners must view the content during the hours posted for the live activity.  This course is not approved for on-demand delivery. 

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.